Fractionated Anti HLA Antibodies Role in Prevention of Sold Organ Transplant Rejection

Overview

About this study

The purpose of this study is to develop single chain variable fragment antibodies against HLA A2 and test their efficacy in blocking the HLA A2 and preventing the immune response.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

≥ 18 years of age.
Highly sensitized patients against HLA A2 undergoing evaluation for heart or lung transplant (MFU >10000).

Exclusion Criteria:

Patients < 18 years of age.
Patients not willing to sign consent.
Patients not currently undergoing evaluation for heart or lung transplant.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/25/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla. Mayo Clinic principal investigator Ian Makey, M.D.	Open for enrollment	Contact information: Mauricia Buchanan R.N. Buchanan.Mauricia@mayo.edu

Mayo Clinic Location

Status

Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Ian Makey, M.D.

Open for enrollment

Contact information:

Mauricia Buchanan R.N.

Buchanan.Mauricia@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials